ORM-6151 (BMS-986497) is currently being clinically evaluated in patients with AML and MDS, while the pre-clinical ORM-1153 may expand Orums presence into additional hematologic malignancies
Wittich CM, Burkle CM, Lanier WL
This medication was shown to reduce the risk of CKD progression and renal failure, as well as dialysis initiation, in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial, which involved participants with type 2 diabetes who had albuminuria and advanced CKD
The randomized, double-blind, placebo-controlled Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimers Disease (ELAD) trial led by Prof
Food and Drug Administration Compounded GLP-1 medications can often be accessed through telehealth services that work with state-licensed compounding pharmacies, which ship directly to patients